Statin use and risk of cholecystectomy – A case-control analysis using Swiss claims data

References

• Völzke H, Baumeister SE, Alte D, et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion. 2005 Jan;71(2):97–105.
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002 May;122(5):1500–1511.
   PubMed Web of Science ®Google Scholar
• Shaffer E. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006 Jan;20(6):981–996.
   PubMed Web of Science ®Google Scholar
• Sylwestrowicz T, Shaffer E. Gallbladder function during gallstone dissolution effect of bile acid therapy in patients with gallstones gastroenterology. Am Gastroenterological Assoc. 1988;95(3):740–748.
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas gastroenterology. AGA Inst Am Gastroenterological Assoc. 2009;136(4):1134–1144.
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases gastroenterology. AGA Inst Am Gastroenterological Assoc. 2009;136(2):376–386.
   PubMed Web of Science ®Google Scholar
• Schneider H, Venetz W. Cost of obesity in Switzerland in 2012. Rheinfelden: DataGen AG; 2014.
   Google Scholar
• Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet (London, England). 2006 Jul 15;368(9531):230–239.
   PubMed Web of Science ®Google Scholar
• Lammert F, Miquel J-F. Gallstone disease: from genes to evidence-based therapy. J Hepatol. 2008 Jan;48(Suppl 1):S124–35.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. Jama. 2015;302(18):2001–2007.
   Google Scholar
• Erichsen R, Frøslev T, Lash TL, et al. Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol. 2011 Jan 15;173(2):162–170.
   PubMed Web of Science ®Google Scholar
• Tsai C-J, Leitzmann MF, Willett WC, et al. Statin use and the risk of cholecystectomy in women gastroenterology. AGA Inst Am Gastroenterological Assoc. 2009 May;136(5):1593–1600.
   PubMed Web of Science ®Google Scholar
• Merzon E, Weiss NS, Lustman AJ, et al. Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf. 2010 Jul;9(4):539–543.
   PubMed Web of Science ®Google Scholar
• Pulkkinen J, Eskelinen M, Kiviniemi V, et al. Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study. BMC Gastroenterol. 2014;14:119.
   PubMed Web of Science ®Google Scholar
• Suuronen S, Niskanen L, Paajanen P, et al. Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009. Scand J Surg. 2013 Jan;102(3):158–163.
   PubMed Web of Science ®Google Scholar
• Chiu H-F, Chen -C-C, Kuo H-W, et al. Statin use and the risk of gallstone disease: a population-based case-control study. Expert Opin Drug Saf. 2012 May;11(3):369–374.
   PubMed Web of Science ®Google Scholar
• Caroli-Bosc F, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation. Dig Dis Sci. 2001;46(3):540–544.
   PubMed Web of Science ®Google Scholar
• Arbeitsgruppe Lipide und Atherosklerose (AGLA). Prävention der Atherosklerose. Switzerland: Swiss Atherosclerosis Association; 2014.
   Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769–1818.
   PubMed Web of Science ®Google Scholar
• Kallien G, Lange K, Stange EF, et al. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology. 1999;30(1):14–20.
   PubMed Web of Science ®Google Scholar
• Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci. 1998;43(2):349–353.
   PubMed Web of Science ®Google Scholar
• Porsch-Ozcurumez M, Hardt PD, Schnell-Kretschmer H, et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol. 2001;56(12):873–879.
   PubMed Web of Science ®Google Scholar
• Smith JL, Roach PD, Wittenberg LN, et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol. 2000;15(8):871–879.
   PubMed Web of Science ®Google Scholar
• Helsana Gruppe. Helsana [Internet]. [ cited 2015 Jan 8]. Available from: http://www.helsana.ch/
   Google Scholar
• Biétry F, Pitzurra R, Schwenkglenks M, et al. Helsana-Arzneimittelreport. 2014. 1–200 p.
   Google Scholar
• Biétry F, Schur N, Pfeil A, et al. Helsana Arzneimittelreport. 2015. 1–200 p.
   Google Scholar
• SwissDRG. abrechnungsversion Swiss diagnosis related groups [internet]. Available from: www.swissdrg.org
   Google Scholar
• Mehra T, Müller CTB, Volbracht J, et al. Predictors of high profit and high deficit outliers under SwissDRG of a tertiary care center. PLoS One. 2015 Jan;10(10):e0140874.
   Google Scholar
• Busse R, Geissler A, Quentin W, et al., Diagnosis-related groups in Europe: moving towards transparency, efficiency. Edited by. 1st Editio. ed. Maidenhead, England: McGraw-Hill, Open University Press; 2011.
   Google Scholar
• World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. The anatomical therapeutic chemical (ATC) and defined daily dosing (DDD) system. [ cited 2014 Jun 27]. Available from: www.whocc.no/atcddd/
   Google Scholar
• Kan H-P, Guo W-B, Tan Y-F, et al. Statin use and risk of gallstone disease: a meta-analysis. Hepatol Res. 2014 Oct;9:942–948.
   Google Scholar
• Lv J, Qi L, Yu C, et al. Gallstone disease and the risk of ischemic heart disease. Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2232–2237.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD. Gallstone disease and increased risk of ischemic heart disease: causal association or epiphenomenon? Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2073–2075.
   PubMed Web of Science ®Google Scholar
• Everson SA, Maty SC, Lynch JW, et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res. 2002 Oct;53(4):891–895.
   PubMed Web of Science ®Google Scholar
• Robbins JM, Vaccarino V, Zhang H, et al. Socioeconomic status and diagnosed diabetes incidence. Diabetes Res Clin Pract. 2005 Jun;68(3):230–236.
   PubMed Web of Science ®Google Scholar
• Gnavi R, Karaghiosoff L, Costa G, et al. Socio-economic differences in the prevalence of diabetes in Italy: the population-based turin study. Nutr Metab Cardiovasc Dis Elsevier Ltd. 2008 Dec;18(10):678–682.
   PubMed Web of Science ®Google Scholar
• Connolly V, Unwin N, Sherriff P, et al. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health. 2000;54:173–177.
   PubMed Web of Science ®Google Scholar
• Documed AG Compendium [Internet]. [ cited 2016 Feb 3]. Available from: www.documed.ch
   Google Scholar
• Festi D, Reggiani MLB, Attili AF, et al. Natural history of gallstone disease: expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 2010 Apr;25(4):719–724.
   PubMed Web of Science ®Google Scholar